A large-scale clinical trial conducted within the Department of Veterans Affairs indicates that analyzing a patient’s genetic makeup can assist medical providers in avoiding antidepressants that may be difficult for the body to process. Patients who underwent this pharmacogenomic testing were more likely to be prescribed medications with fewer predicted negative interactions.
Additionally, these patients experienced a modest but statistically significant improvement in the remission of their depression symptoms compared to those receiving standard care. The findings of this research were published in the Journal of the American Medical Association.
Major depressive disorder is a pervasive and debilitating health condition that affects millions of adults. Symptoms often include persistent sadness, loss of interest in activities, insomnia, changes in appetite, and in severe cases, thoughts of suicide. Finding the right medication to manage these symptoms is frequently a challenge.
Current clinical practice largely relies on a trial-and-error approach, where a patient tries a medication for several weeks to see if it works. If the first drug fails or causes intolerable side effects, the patient and doctor must start over with a new prescription.
This iterative process can be discouraging and prolongs the period of suffering for the patient. Consequently, medical science has sought ways to personalize this process. Pharmacogenomics is the study of how a person’s genes affect their body’s response to drugs.
While this type of testing is increasingly common in treating cancer and heart disease, its application in psychiatry has been a subject of ongoing debate. The goal is to use a patient’s genetic profile to predict how they will metabolize specific drugs, thereby reducing the guesswork involved in prescribing.
The researchers behind this study sought to determine if providing clinicians with immediate access to pharmacogenomic data would lead to better medication choices and improved patient outcomes in a real-world setting. Previous research on this topic has been limited or produced mixed results, leaving providers unsure about the clinical utility of these tests.
The study team aimed to move beyond theoretical benefits and assess whether this technology actually helps patients recover from depression more effectively than usual care.
“Treating Veterans and other patients with major depressive disorder can prove challenging. There are many medications a physician can choose from, but patients respond differently to these medicines,” said David Oslin, director of VA’s VISN 4 Mental Illness, Research, Education, and Clinical Center (MIRECC), who led the study.
“Achieving a remission can take months as clinicians use a trial-and-error process to identify an effective medication. We need a better way of targeting treatments. There is a lot of promise in how genetics might help in selecting medications. Genetic tests are commercially available, but there was only limited evidence on how they would work in clinical practice. Our research aimed to change this.”
To investigate this, the research team recruited nearly 2,000 veterans diagnosed with major depressive disorder. The study took place across 22 Veterans Affairs medical centers, ensuring a diverse range of clinical settings.
The participants were patients who were either initiating a new treatment for depression or switching medications due to lack of success with a previous drug. The researchers employed a randomized method to divide the participants into two groups.
The first group, referred to as the pharmacogenomic-guided group, received genetic testing immediately. Their doctors were given the results to help inform their prescribing decisions. The second group served as the control and received usual care.
These patients also underwent genetic testing, but the results were not shared with their providers for 24 weeks. This design allowed the researchers to compare the outcomes of genetically informed prescribing against standard clinical judgment.
The testing process itself was non-invasive. Patients provided a DNA sample using a simple cheek swab. The researchers utilized a commercial genetic test panel that analyzes variants in genes encoding cytochrome P450 enzymes. These liver enzymes are responsible for metabolizing many common medications.
The test results categorized antidepressants based on how the patient’s specific genetic profile would likely interact with them. Medications were labeled as having no predicted interaction, moderate interaction, or substantial interaction.
The results of the study provided evidence that access to genetic information altered how doctors prescribed medications. In the group with access to test results, there was a marked shift away from drugs that had predicted negative interactions.
Specifically, 59 percent of patients in the guided group received a medication with no predicted drug-gene interaction. In contrast, only 26 percent of patients in the usual care group received a medication with no predicted interaction.
The researchers also observed that patients in the guided group were far less likely to be prescribed a drug with a “substantial” interaction risk. This suggests that without the genetic data, clinicians frequently prescribe medications that a patient’s body may struggle to process efficiently. The study highlights that having this biological information empowers providers to make more precise decisions regarding dosage and drug selection.
Regarding clinical improvement, the study measured outcomes using standard depression severity scales over a period of 24 weeks. The researchers found that the group receiving genetically guided care showed better rates of symptom remission and response.
The benefit was most notable during the earlier phases of treatment, specifically at the 8-week and 12-week check-ins. This indicates that using genetic insights may speed up the process of finding an effective treatment.
“Pharmacogenomics, understanding how a person’s genetics affect the response to medications, can assist clinicians in getting Veterans the care they need sooner than through trial and error,” Oslin told PsyPost. “Genetic testing can identify a small number of people for whom selecting an alternative antidepressant will lead to faster treatment outcomes.”
However, the difference between the two groups narrowed by the end of the six-month study period. At the 24-week mark, the statistical difference in remission rates was no longer significant.
This convergence suggests that the usual care group eventually began to catch up, likely because their doctors adjusted medications based on the patient’s clinical response over time. The genetic testing appeared to act as a shortcut, helping patients reach a better therapeutic state faster than they would have through standard trial and error.
Oslin noted that the results were not a “slam dunk” for every single patient but offered a clear benefit for some. He pointed out that only about 15 to 20 percent of patients possess the specific genetic variants that would significantly interfere with standard medications.
For the remaining majority, the test might not prompt a change in prescription. Nevertheless, for the minority of patients with these variants, avoiding a mismatched drug can be quite meaningful.
“A relatively small number of patients with major depressive disorder will benefit from genetic testing,” Oslin explained. “But when results indicate an alternative medicine for a patient is better suited, the effect on that patient can be substantial. Because the cost of testing is low and tests have to be done just once in a patient’s lifetime, we believe the benefits outweigh the costs.”
The study also revealed that patients suffering from post-traumatic stress disorder (PTSD) alongside their depression had a harder time achieving remission. This was true regardless of whether they received genetic testing or not.
The presence of PTSD appeared to be a strong factor in treatment resistance, suggesting that comorbidities play a significant role in how well a patient responds to antidepressant therapy.
There are some caveats to how these results should be interpreted. A common misunderstanding is that pharmacogenomic testing tells a doctor which drug will cure the patient’s depression. “The tests don’t do that,” Oslin noted. “Instead, they tell providers about the metabolism of the medication itself, not about the patient’s depression or anxiety.”
In other words, pharmacogenomic testing can indicate if a patient will break down a medication too quickly, rendering it ineffective, or too slowly, causing it to build up to toxic levels.
The authors also acknowledged limitations in the study design. The trial was not blinded, meaning both the doctors and the patients knew who had access to the test results. This awareness introduces the possibility of a placebo effect, where patients feel better simply because they know they are receiving a technologically advanced, personalized treatment.
Despite these limitations, the study suggests that pharmacogenomic testing carries a low risk and offers potential benefits. The burden on the patient is minimal, involving only a cheek swab, and the cost is relatively low considering the results remain valid for the patient’s lifetime.
Future research will likely focus on identifying which specific subgroups of patients stand to gain the most from this testing, allowing for even more targeted application of the technology.
“Our work reinforced once again the critical role of continuing professional education and ongoing training particularly as new techniques emerge,” Oslin said. “Bringing the insights of research into clinical practice entails working closely with providers to ensure they understand the results and implications of pharmacogenomic testing as they seek to care for Veterans struggling with major depressive disorder.”
The study, “Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial,” was authored by David W. Oslin, Kevin G. Lynch, Mei-Chiung Shih, Erin P. Ingram, Laura O. Wray, Sara R. Chapman, Henry R. Kranzler, Joel Gelernter, Jeffrey M. Pyne, Annjanette Stone, Scott L. DuVall, Lisa Soleymani Lehmann, and Michael E. Thase.
